Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess the Immunogenicity Consistency of Three Consecutive Batches of Commercial-scale of Recombinant Human Papillomavirus(HPV) Bivalent Vaccine (Escherichia Coli) in Healthy Female Subjects Aged 9-14 Years

NCT05426148 is registered in ClinicalTrials.gov with Xiamen Innovax Biotech Co., Ltd as lead sponsor.

NCT NCT05426148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05426148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess the Immunogenicity Consistency of Three Consecutive Batches of Commercial-scale of Recombinant Human Papillomavirus(HPV) Bivalent Vaccine (Escherichia Coli) in Healthy Female Subjects Aged 9-14 Years
Lead sponsor
Xiamen Innovax Biotech Co., Ltd
Phase
Phase 4
Overall status
Completed
Start date
May 1, 2020
Completion date
April 30, 2021
Enrollment
540 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, cervical intraepithelial neoplasia, persistent infection, vaginal intraepithelial neoplasia, vulvar intraepithelial neoplasia